Its the second daily oral medication to treat obesity and other weight-related conditions (Novo Nordisks oral Wegovy was the first) allowing patients to avoid having to give themselves injections
Bradway also said Amgen is studying the efficacy of a range of different doses, adding that "we want to understand what will it take for patients to stay on this therapy, because persistence is the name of the game." Bradway also touched on Amgen's acquisition of Horizon Therapeutics, saying the deal is working well in part because it plays to his company's strengths biologics and autoimmunity
Athletes turn to CJC-1295 for improved performance, while many aging adults report a boost in energy, better sleep, and improved physical function
Under the expert guidance of Rosaly Stephens, ARNP-C, we help patients navigate their weight loss journey using GLP-1 receptor agonists like Semaglutide, ensuring that every step is monitored for safety, comfort, and long-term success
doi: 10.1021/am101118h